MUSCULAR WEAKNESS

Adverse reaction reported in 30,350 FDA reports across 21 drugs.

30,350
Total Reports
21
Drugs Involved
Natalizumab
Most Reported Drug

Drugs Associated with MUSCULAR WEAKNESS

Drugs where "MUSCULAR WEAKNESS" was reported as an adverse event.

# Drug Reports % of Total
1 Natalizumab 4,589
15.1%
2 Interferon Beta-1a 4,082
13.4%
3 Dalfampridine 2,785
9.2%
4 Baclofen 2,340
7.7%
5 Fingolimod 2,203
7.3%
6 Teriparatide 2,142
7.1%
7 Onabotulinumtoxina 1,781
5.9%
8 Ocrelizumab 1,663
5.5%
9 Ezetimibe 1,499
4.9%
10 Teriflunomide 1,271
4.2%
11 Enzalutamide 1,006
3.3%
12 Botulinum Toxin Type A 950
3.1%
13 Ofatumumab 862
2.8%
14 Alemtuzumab 609
2.0%
15 Felodipine 489
1.6%
16 Felodipine Extended- 489
1.6%
17 Ravulizumab 468
1.5%
18 Interferon Beta-1b 438
1.4%
19 Siponimod 243
0.8%
20 Peginterferon Beta-1a 230
0.8%
21 Bupivacaine 211
0.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. The presence of a drug in this list does not mean the drug caused muscular weakness. Always consult your healthcare provider.